| ID Source | ID |
|---|---|
| PubMed CID | 2726559 |
| CHEMBL ID | 1350622 |
| CHEBI ID | 111253 |
| SCHEMBL ID | 1230231 |
| Synonym |
|---|
| 5-(2-chloroanilino)-3-hydroxyisothiazole-4-carbonitrile |
| smr000456711 |
| MLS000850694 , |
| 4-isothiazolecarbonitrile, 5-[(2-chlorophenyl)amino]-2,3-dihydro-3-oxo- |
| 5-(2-chloroanilino)-3-oxo-isothiazole-4-carbonitrile |
| OPREA1_535626 |
| CHEBI:111253 |
| HMS1666L12 |
| 5-(2-chloroanilino)-3-oxo-1,2-thiazole-4-carbonitrile |
| CCG-1980 |
| BRD-K25471411-001-07-7 |
| HMS2780G09 |
| FT-0619581 |
| 287196-71-8 |
| SCHEMBL1230231 |
| CHEMBL1350622 |
| 5-(2-chloroanilino)-3-oxo-4-isothiazolecarbonitrile |
| bdbm61727 |
| cid_2726559 |
| 5-(2-chloroanilino)-3-keto-4-isothiazoline-4-carbonitrile |
| 5-[(2-chlorophenyl)amino]-3-oxidanylidene-1,2-thiazole-4-carbonitrile |
| Q27190868 |
| DTXSID90369411 |
| 5-(2-chloroanilino)-3-hydroxyisothiazole-4-carbonitrile, aldrichcpr |
| 5-(2-chlorophenylamino)-3-hydroxyisothiazole-4-carbonitrile |
| Class | Description |
|---|---|
| substituted aniline | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 3.1623 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 25.1189 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 0.7943 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 26.8545 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 35.4813 | 0.0184 | 6.8060 | 14.1254 | AID624172 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 3.9811 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 5.8024 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| GLS protein | Homo sapiens (human) | Potency | 10.0000 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 9.8773 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 8.4279 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 39.8107 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 44.6684 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| IDH1 | Homo sapiens (human) | Potency | 16.3601 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 7.9433 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 22.3872 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 16.8336 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 2.2106 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 3.5481 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
| geminin | Homo sapiens (human) | Potency | 20.7329 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 31.6228 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 17.7828 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 12.5893 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 4.7600 | 0.0042 | 7.4680 | 21.1000 | AID2073 |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 4.7600 | 0.0003 | 7.3294 | 21.1000 | AID2073 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| hypothetical protein CAALFM_CR05890CA | Candida albicans SC5314 | AC50 | 4.2100 | 1.5500 | 13.0038 | 54.7000 | AID588764 |
| H3 histone acetyltransferase | Candida albicans SC5314 | AC50 | 4.2100 | 1.5500 | 13.0038 | 54.7000 | AID588764 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||